Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
Clinical role
WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
Images and patients
Ultrasound · Heart and left atrial appendage
Key limitation
Keep in mind: The software is an aid during the labeled procedure and does not make autonomous clinical decisions; final planning and sizing remain with the healthcare professional.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart and left atrial appendage Input: Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.
Who uses it?Intended users: Healthcare professionals performing left-atrial-appendage closure.
What does the software produce?Output: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
What is its most important limitation?Key limitation: The software is an aid during the labeled procedure and does not make autonomous clinical decisions; final planning and sizing remain with the healthcare professional.
Clinical takeaway. Clinical role: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a prospective multicenter clinical study of 100 subjects enrolled across 6 U.S. centers (72 per-protocol), comparing WatchMate measurements from 2D TEE input against a unanimous-consensus three-reader contrast-enhanced CT reference standard. For the primary endpoint, landing zone maximum diameter, mean absolute deviation vs. CT was 3.1 ± 3.4 mm for WatchMate and 5.2 ± 3.4 mm for physician-interpreted 2D TEE (difference –2.1 mm, upper 97.5% CI -0.9 mm), meeting the 1 mm non-inferiority margin. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
The software is an aid during the labeled procedure and does not make autonomous clinical decisions; final planning and sizing remain with the healthcare professional.
The exact FDA document reports a prospective multicenter clinical study of 100 subjects enrolled across 6 U.S. centers (72 per-protocol), comparing WatchMate measurements from 2D TEE input against a unanimous-consensus three-reader contrast-enhanced CT reference standard. For the primary endpoint, landing zone maximum diameter, mean absolute deviation vs. CT was 3.1 ± 3.4 mm for WatchMate and 5.2 ± 3.4 mm for physician-interpreted 2D TEE (difference –2.1 mm, upper 97.5% CI -0.9 mm), meeting the 1 mm non-inferiority margin. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "a prospective multicenter clinical study confirmed its non-inferior performance to the average of three blinded physician-interpreted 2D TEE readers against a unanimous-consensus three-reader CT reference standard, for LAAC landing-zone measurement." … "The study was designed to validate WatchMate measurements of left atrial appendage (LAA) anatomy using intra-procedural 2D transesophageal echocardiography (TEE) as input and contrast-enhanced computed tomography (CT) as the reference standard.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a prospective multicenter clinical study of 100 subjects enrolled across 6 U.S. centers (72 per-protocol), comparing WatchMate measurements from 2D TEE input against a unanimous-consensus three-reader contrast-enhanced CT reference standard. For the primary endpoint, landing zone maximum diameter, mean absolute deviation vs. CT was 3.1 ± 3.4 mm for WatchMate and 5.2 ± 3.4 mm for physician-interpreted 2D TEE (difference –2.1 mm, upper 97.5% CI -0.9 mm), meeting the 1 mm non-inferiority margin. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "a prospective multicenter clinical study confirmed its non-inferior performance to the average of three blinded physician-interpreted 2D TEE readers against a unanimous-consensus three-reader CT reference standard, for LAAC landing-zone measurement." … "The study was designed to validate WatchMate measurements of left atrial appendage (LAA) anatomy using intra-procedural 2D transesophageal echocardiography (TEE) as input and contrast-enhanced computed tomography (CT) as the reference standard.". Read from the exact FDA decision document on 2026-11-14.
No exact-product, version-specific sensitivity endpoint was established for this submission in the evidence set.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K260300 FDA evidence package for WatchMate Software
DesignFDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation.
PopulationPopulation and workflow are limited to the exact FDA labeling summarized for this submission.
Scopeexact submission
Tested versionExact FDA submission release; version not separately stated in the public decision material
IndependenceSponsor or vendor study
K260300
Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K260300 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound echo data acquired with the supported transducers, exam modes, and labeled patient or anatomy scope.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Processes two-dimensional transesophageal echocardiography data to produce a three-dimensional left-atrial-appendage reconstruction; the full facility interface contract remains to be tested.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Deployment details for the exact cleared configuration are not established in the public FDA decision material.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Ultrasound images, measurements, flow information, or clinician-reviewed analyses described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Processes two-dimensional transesophageal echocardiography data to produce a three-dimensional left-atrial-appendage reconstruction; the full facility interface contract remains to be tested.
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
Processes two-dimensional transesophageal echocardiography data to produce a three-dimensional left-atrial-appendage reconstruction; the full facility interface contract remains to be tested.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The software is an aid during the labeled procedure and does not make autonomous clinical decisions; final planning and sizing remain with the healthcare professional.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04
Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-19Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not verified - checked 2026-09-04 - Exact FDA submission
Deployment details for the exact cleared configuration are not established in the public FDA decision material.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.
Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.
Authorized purpose: EPIQ diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, vascular, small-organ, and urologic examinations.
Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; and urologic organs
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.